Plasma disposition and tolerance of aditoprim in horses after single intravenous injection.

The research investigated the impact of an antimicrobial agent called aditoprim on horses, which was given through an intravenous injection, and found it was well-tolerated and had beneficial antibacterial effects.

Research Methodology

• The study was conducted on four horses aged between 12 to 24 years old.
• An intravenous injection of aditoprim, an antimicrobial agent that acts as a reversible dihydrofolate reductase inhibitor, was administered at a dosage of 5 mg/kg of body weight.
• Blood samples were collected over a 48-hour period to measure the drug’s concentration.
• The researchers also recorded each horse’s body temperature, heart rate, respiration rate, and behaviour during the experiment.
• Furthermore, the concentrations of bilirubin and urea were determined in the plasma samples, and liver function tests were carried out.

Research Results

• The concentrations of aditoprim in the plasma of the horses were noteworthy against isolated pathogens for a duration of 6-13 hours (for Pasteurella haemolytica A 1) to 48 hours (for E. coli).
• The drug showed a large volume of distribution (mean value of 7.8 l/kg), a mean plasma clearance of 5.0 l/minute, and a plasma elimination half-life of 12 hours.
• Clinical observations, blood chemistry results, and liver function tests indicated that the drug had been well-tolerated by the horses, despite being injected intravenously in a 25% solution.

Conclusions

• The researchers concluded that the 25% aditoprim injection solution could be used in horses without adverse effects at a dosage of 5 mg/kg.
• They expected that aditoprim would show good antibacterial effects in horses when it’s intravenously injected once a day.